Recurrent Metastatic HNSCC

Advertisement

cGxPJobs Banner

Pyxis Oncology Advances MICVO Toward Phase 3 in HNSCC

BOSTON — September 9, 2026 Pyxis Oncology, Inc. announced positive updated data from its ongoing Phase 1 monotherapy study...

By cGxPwire Editor
September 11, 2026

Read More

Advertisement

cGxPJobs

Directory